These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12660522)

  • 1. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis.
    Kulkarni S; Naureckas E; Cronin DC
    Transplantation; 2003 Mar; 75(6):899-901. PubMed ID: 12660522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drotrecogin alfa (activated).
    Lyseng-Williamson KA; Perry CM
    Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case series of drotrecogin alfa (activated) in lung transplant recipients.
    Daniels TL; Dummer JS; Bernard GR; Milstone AP
    Transplantation; 2006 Jun; 81(12):1739-42. PubMed ID: 16794542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.
    Berkman S; Weimert NA; Taber DJ; Baillie GM; Lin A; Baliga P; Chavin KD
    Transpl Infect Dis; 2009 Jun; 11(3):269-76. PubMed ID: 19392728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant.
    Browne E; Cressey DM; Agarwal K; Cosgrove JF
    Anaesthesia; 2007 Mar; 62(3):282-5. PubMed ID: 17300307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies.
    Machała W; Wachowicz N; Komorowska A; Gaszyński W
    Med Sci Monit; 2004 Jul; 10(7):CS31-6. PubMed ID: 15232511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Titrated dose of drotrecogin alpha for liver transplant recipient.
    Saluja V; Pandey V; Pandey CK; Singhal A
    J Postgrad Med; 2012; 58(4):330-1. PubMed ID: 23298940
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
    Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
    Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
    Pastores SM; Papadopoulos E; van den Brink M; Alicea M; Halpern NA
    Bone Marrow Transplant; 2002 Jul; 30(2):131-4. PubMed ID: 12132053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
    Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
    Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated recombinant protein C in septic shock early after liver transplantation: a case report.
    Feltracco P; Bortolato A; Rizzi S; Barbieri S; Furnari M; Serra E; Milevoj M; Ori C
    Transplant Proc; 2008; 40(6):2070-2. PubMed ID: 18675133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated) in severe falciparum malaria.
    Kendrick BJ; Gray AG; Pickworth A; Watters MP
    Anaesthesia; 2006 Sep; 61(9):899-902. PubMed ID: 16922759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
    Laterre PF; Wittebole X
    Crit Care; 2003 Dec; 7(6):445-50. PubMed ID: 14624684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of drotrecogin alfa (activated) treatment in severe sepsis.
    Choi G; de Pont AC; Schultz MJ
    Crit Care; 2006; 10(4):419; author reply 419. PubMed ID: 16934134
    [No Abstract]   [Full Text] [Related]  

  • 19. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
    Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
    N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
    Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.